

***Fiscal Year 2025 Department of Defense Melanoma Research Program (MRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Focused Program Award – Rare Melanomas</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525MRPFARM</p>	<p>The Initiating Principal Investigator (PI) must be an independent investigator at or above the level of Associate Professor (or equivalent).</p> <p>The Partnering PI(s) (i.e., Project Leader[s]) for the complementary and synergistic research project[s]) must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • **NEW for FY25** Submission of a preproposal is required; application submission is by invitation only. • Application MUST propose a unifying, overarching question that addresses a critical unmet need relevant to <i>rare melanoma</i> research and/or patient care, with the ultimate goal to translate laboratory findings to clinical applications. • Supports a synergistic, multidisciplinary research program of at least two but not more than three distinct but complementary projects. The completion of one project should not be dependent on the completion of another project. • Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching question. • Research team should be led by an Initiating PI with demonstrated success in directing large, focused projects. • Applicants are encouraged, but not required, to include at least one rare melanoma consumer collaborator as part of the project team who will provide advice and consultation throughout the planning and implementation of the effort to optimize research impact and translatability. • <i>Clinical trials ARE allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2,800,000 for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): June 30, 2025 5:00 p.m. Eastern time</p> <p>Application: October 1, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525MRPIA</p>	<p>Investigators at or above the level of Postdoctoral Fellow, or equivalent.</p> <p>Investigators new to the melanoma field are encouraged.</p>	<ul style="list-style-type: none"> • **Returning for FY25** Submission of a preproposal is required; application submission is by invitation only. • Supports new ideas that represent high-risk/high-gain approaches to melanoma research that are beyond an incremental advancement. • Emphasis is on innovation and potential impact. Incremental advances, the next logical step of existing lines of research in the PI's laboratory or merely switching the object or method of inquiry from one cancer to another cancer are not considered innovative. • Must address at least one of the FY25 focus areas. • <i>Preliminary data are discouraged.</i> • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$560,000 for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): June 30, 2025 5:00 p.m. Eastern time</p> <p>Application: October 1, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Melanoma Academy Leadership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525MRPMALA</p>	<p>Both the Director and Deputy Director must be established, independent melanoma investigators.</p>	<ul style="list-style-type: none"> • A letter of intent is required; an invitation to submit a full application is <i>not</i> required. • Supports visionary individuals who are established melanoma investigators with a strong record of mentoring and a commitment to leadership. • The Melanoma Academy Director with Deputy Director will continue the development and execution of an interactive network of early career investigators (Scholars) whose goals include building independent and collaborative careers in the melanoma field. • The Director and Deputy Director will facilitate regular interactive communication and collaboration among all Melanoma Academy members. • Develop evaluation plans to assess the progress of the Scholars and the Melanoma Academy towards stated goals. • Maintain a Melanoma Consumer Consultant Panel to inform the Melanoma Academy on the needs of the melanoma community. • Clinical trials are not allowed. <p><i>Early-career investigators interested in joining the Melanoma Academy should apply to the Melanoma Academy Scholar Award (see below).</i></p>	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,820,000 for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): September 10, 2025 5:00 p.m. Eastern time</p> <p>Application: October 1, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Melanoma Academy Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525MRPMASA</p>	<p>Investigators must be within seven years of first <i>faculty appointment</i> as of the full application submission deadline.</p> <p>A letter attesting to eligibility is required.</p>	<ul style="list-style-type: none"> • A letter of intent is required; an invitation to submit a full application <i>is not</i> required. • Supports the addition of new Scholars to the unique, interactive virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for early-career melanoma investigators/faculty. • Requires a Career Guide who is an experienced melanoma researcher with melanoma funding. • A Career Guide may only mentor one Scholar. • The Career Guide is not required to be at the same institution as the Scholar. • The Career Guide must be committed to participating in the Melanoma Academy, to include serving in advisory roles as requested by Academy Leadership. • Must address at least one of the FY25 focus areas. • Preliminary data are not required. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$770,000 for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 10, 2025 5:00 p.m. Eastern time</p> <p>Application: October 1, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Survivorship Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525MRPSRA</p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> A letter of intent is required; an invitation to submit a full application is <i>not</i> required. Supports a broad range of innovative and impactful survivorship research that has the intended outcome of improving the health and well-being of melanoma survivors (active- or post-treatment), their families and/or their caregivers. Areas of survivorship research of interest to the MRP include, but are not limited to: <ul style="list-style-type: none"> Preservation of function and symptom management throughout treatment and beyond Psychological and social impacts of a melanoma diagnosis and treatment Treatment outcomes Health care delivery The research team is <i>required</i> to collaborate with the melanoma consumer community (e.g., melanoma survivors, caregivers) to optimize research impact and translatability through inclusion of a melanoma consumer, partnership with a community-supporting organization or establishment of a community advisory board. <i>Clinical trials ARE allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$1,015,000 for total costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 10, 2025 5:00 p.m. Eastern time</p> <p>Application: October 1, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Team Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525MRPTSA</p>	<p>Two or three independent investigators at or above the level of Assistant Professor (or equivalent) must partner in one multidisciplinary research study</p> <p>Inclusion of at least one military, VA investigator, or early-career investigator is encouraged</p>	<ul style="list-style-type: none"> • **NEW for FY25** Submission of a preproposal is required; application submission is by invitation only. • Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts. • Each PI should have equal intellectual input into the design <i>and</i> execution of the project. • Intended to fund a broad range of studies including, but not limited to, the following: <ul style="list-style-type: none"> ◦ Translational research ◦ Data science research ◦ Projects focusing on bioengineering approaches ◦ Other hypothesis-driven basic to translational studies • Emphasis is on multi-disciplinary research and the short- and long-term impact of the effort on the melanoma research field and/or patient care. • Must address at least one of the FY25 focus areas. • Preliminary data <i>are</i> required. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2,100,000 for total costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 30, 2025 5:00 p.m. Eastern time</p> <p>Application: October 1, 2025 11:59 p.m. Eastern time</p>